← Back to Screener
Incyte Genomics Inc (INCY)
Price$96.92
Favorite Metrics
Price vs S&P 500 (26W)7.98%
Price vs S&P 500 (4W)-1.74%
Market Capitalization$19.30B
P/E Ratio (Annual)15.00x
All Metrics
P/CF (Annual)13.65x
Book Value / Share (Quarterly)$26.04
P/TBV (Annual)3.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.84%
Cash Flow / Share (Quarterly)$6.83
Price vs S&P 500 (YTD)-5.10%
Gross Margin (TTM)93.26%
Net Profit Margin (TTM)25.03%
EPS (TTM)$6.40
10-Day Avg Trading Volume1.28M
EPS Excl Extra (TTM)$6.40
Revenue Growth (5Y)14.03%
EPS (Annual)$6.41
ROI (Annual)24.73%
Gross Margin (Annual)93.26%
Net Profit Margin (5Y Avg)16.76%
Cash / Share (Quarterly)$18.04
P/E Basic Excl Extra (TTM)15.00x
Revenue Growth QoQ (YoY)27.84%
P/E Normalized (Annual)15.00x
ROA (Last FY)18.49%
Revenue Growth TTM (YoY)21.22%
EBITD / Share (TTM)$7.80
ROE (5Y Avg)14.06%
Operating Margin (TTM)29.46%
Cash Flow / Share (Annual)$6.83
P/B Ratio3.73x
P/B Ratio (Quarterly)3.75x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.16x
Net Interest Coverage (TTM)6.86x
ROA (TTM)20.70%
EPS Growth QoQ (YoY)50.38%
EV / EBITDA (TTM)10.37x
EPS Incl Extra (Annual)$6.41
Current Ratio (Annual)3.32x
Quick Ratio (Quarterly)3.04x
3-Month Avg Trading Volume1.84M
52-Week Price Return69.44%
EV / Free Cash Flow (Annual)11.98x
P/E Incl Extra (TTM)15.00x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$25.45
P/S Ratio (Annual)3.75x
Asset Turnover (Annual)0.74x
52-Week High$112.29
Operating Margin (5Y Avg)16.88%
EPS Excl Extra (Annual)$6.41
CapEx CAGR (5Y)-20.67%
Tangible BV CAGR (5Y)15.67%
26-Week Price Return16.73%
Quick Ratio (Annual)3.04x
13-Week Price Return-7.67%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)3.32x
Enterprise Value$16,233.363
Revenue / Share Growth (5Y)15.94%
Asset Turnover (TTM)0.83x
Book Value / Share Growth (5Y)16.96%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)4.33x
Pretax Margin (Annual)32.37%
Cash / Share (Annual)$18.04
3-Month Return Std Dev31.50%
Gross Margin (5Y Avg)94.07%
Net Income / Employee (TTM)$0
EBITDA Interim CAGR (5Y)15.49%
ROE (Last FY)24.90%
Net Interest Coverage (Annual)12.38x
EPS Basic Excl Extra (Annual)$6.41
P/FCF (TTM)14.24x
Receivables Turnover (TTM)5.48x
EV / Free Cash Flow (TTM)11.98x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$6.40
Receivables Turnover (Annual)5.48x
ROI (TTM)28.91%
P/S Ratio (TTM)3.75x
Pretax Margin (5Y Avg)19.42%
Revenue / Share (Annual)$25.62
Tangible BV / Share (Annual)$25.45
Forward P/E13.19x
Price vs S&P 500 (52W)34.35%
P/E Ratio (TTM)15.00x
EPS Growth TTM (YoY)2749.07%
Year-to-Date Return-0.96%
5-Day Price Return2.38%
EPS Normalized (Annual)$6.41
ROA (5Y Avg)10.59%
Net Profit Margin (Annual)25.03%
Month-to-Date Return3.93%
Cash Flow / Share (TTM)$2.23
EBITD / Share (Annual)$7.80
EPS Growth (3Y)61.53%
Operating Margin (Annual)29.46%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)13.65x
ROI (5Y Avg)13.96%
P/E Excl Extra (TTM)15.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$6.40
P/TBV (Quarterly)3.84x
P/B Ratio (Annual)3.75x
Inventory Turnover (TTM)4.33x
Pretax Margin (TTM)32.37%
Book Value / Share (Annual)$26.04
Price vs S&P 500 (13W)-10.54%
Beta0.83x
P/FCF (Annual)14.24x
Revenue / Share (TTM)$25.13
ROE (TTM)29.15%
52-Week Low$56.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.78
3.75
3.76
3.70
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
INCYIncyte Genomics Inc | 15.00x | 29.15% | 14.03% | — | $96.92 |
IQVIQVIA Holdings Inc. | 22.06x | 22.28% | 7.50% | — | $176.76 |
MEDPMedpace Holdings, Inc. Common Stock | 32.96x | 118.82% | 22.27% | — | $528.44 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $185.54 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.95 |
NRCNational Research Corporation Common Stock (Delaware) | 35.35x | 58.51% | 0.61% | 3.55% | $18.18 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.55 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.86 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.29 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.13 |
About
Incyte is a biopharmaceutical company specializing in small-molecule therapies for oncology, rheumatology, and dermatology. Jakafi, its flagship product for rare blood cancers and graft versus host disease, is co-developed with Novartis. The company markets multiple approved drugs including Olumiant (with Eli Lilly), Iclusig, Pemazyre, Tabrecta, Monjuvi, and the dermatology product Opzelura for atopic dermatitis and vitiligo. Its pipeline includes additional oncology and dermatology candidates.